Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation
The study will evaluate the efficacy, safety and tolerability of prucalopride over 12 weeks of treatment in subjects aged 18 years and older with chronic non-cancer pain, suffering from opioid induced constipation.
Non-cancer Pain|Opioid Induced Constipation
DRUG: placebo|DRUG: prucalopride
Percent of Subjects With an Average Frequency of >=3 Spontaneous Bowel Movements Per Week, A bowel movement (BM) was defined as spontaneous if no laxatives were taken in the 24 hours preceding that BM., 12 weeks
Plasma Concentration of Prucalopride at Week 2, Week 2|Plasma Concentration of Prucalopride at Week 8, Week 8
The study will evaluate the efficacy, safety and tolerability of prucalopride over 12 weeks of treatment in subjects aged 18 years and older with chronic non-cancer pain, suffering from opioid induced constipation.